Medical care comes before the reporting form
A safety report is useful, but it is not a clinical assessment. Seek urgent medical care for severe symptoms or a suspected emergency. Contact the prescriber about a new or concerning reaction and have the medication details available. Do not wait for a retailer to decide whether your experience qualifies for a refund before getting appropriate medical attention.
For background, see peptide safety evidence before applying a general claim to a particular product.
Once immediate care is addressed, a clear account can help the clinician, pharmacist and regulator understand what happened. FDA’s MedWatch program accepts reports involving serious reactions, product quality problems, therapeutic failure and product-use errors. [1] Those categories are broader than a familiar list of expected side effects. A confusing label or incorrect product can be relevant even when the main concern is how it was used.
You do not need to establish causation first
A report describes a suspected association. It does not prove that the product caused the symptoms. Include other medicines, relevant conditions and the sequence of events so the information can be evaluated. State uncertainty plainly. If you do not know the administered amount or the exact time, report what you know rather than inventing a precise number.
FDA encourages consumers to work with a clinician because medical records can make a report more informative. It also says patients may complete an online report themselves when a clinician does not do so. [1] A provider’s refusal to file a report does not prevent you from submitting your own account through the consumer reporting pathway.
Save the information that identifies the product
Keep the dispensing pharmacy’s name, product name, prescription number, concentration, lot number, beyond-use date and photographs of the label and packaging. Note whether the product was compounded and whether other ingredients were listed. Preserve the actual instructions, including the syringe type if relevant. A platform’s brand name alone may not identify who prepared the medication.
Write down when the package arrived, how it was stored, when the vial was first accessed and when symptoms began. Distinguish an observation from an interpretation. “The parcel felt warm” is an observation; “heat caused my reaction” is a conclusion that needs evidence. Both the clinical team and a safety reviewer benefit from a record that keeps those separate.
Describe an administration error as an error
If the label and instructions disagreed, include both. If you used a different syringe or followed old refill instructions, explain that sequence. FDA has documented compounded semaglutide errors involving different concentrations and confusion between milligrams, milliliters and units. [2] Reporting the instructional problem can be as valuable as describing the symptoms that followed it.
Avoid reconstructing the intended amount using an online chart from another pharmacy. Ask the pharmacist to identify the current preparation and document any correction. Save the original directions before they are replaced. A detailed timeline makes it easier to distinguish a dispensing issue, a prescribing calculation, a misunderstanding and an unrelated medical event without assigning blame prematurely.
Use the official reporting route
Start from FDA’s Reporting Serious Problems page and follow its consumer reporting instructions. The page links the online reporting option and the consumer form, FDA 3500B. [1] Do not put your prescription details or identifying medical records in a public review in place of a regulatory report. Use the official form and appropriate clinical channels for sensitive information.
A report to customer service is separate from a report to FDA. A refund conversation, a credit-card dispute and a safety report also serve different purposes. You may need more than one route, but none substitutes for necessary care. Keep copies of what you submit and record when you contacted the pharmacy and prescriber.
What a report can and cannot establish
FDA uses reports as part of safety surveillance. [1] An individual report can identify a possible issue that deserves investigation, but a count of reports cannot by itself establish how common a reaction is. The number of exposed users, duplicate reports and other explanations may be uncertain. Absence of reports is not proof that an unapproved product is safe.
For compounded GLP-1 products, FDA specifically encourages reporting adverse events and medication errors. [2] Its current warning also explains why unapproved preparations raise quality and safety questions. [3] The useful goal is an accurate record: the exact product, the exact concern and the circumstances. That helps professionals investigate without turning a suspected association into an unsupported certainty.
Read the evidence in context
See peptide safety evidence for the related details and source material.
See how dosing errors happen for the related details and source material.
See opened-vial discard limits for the related details and source material.